{"id":"5e7f7d21-4509-40b0-b39d-acd6e2f5ce07","companyId":"1942437f-dbb8-4059-9dcb-6b87817b7950","modelName":"Wandercraft Eve","slug":"wandercraft-eve","description":"Personal-use self-balancing walking exoskeleton from [Wandercraft](/companies/wandercraft), the take-home counterpart to the clinic-based [Atalante X](/models/wandercraft-atalante-x). Like Atalante it walks hands-free, without crutches, using AI-driven dynamic balance. The FDA cleared Eve in August 2026 for eligible adults with spinal cord injuries at any level, provided the user can operate the device's remote control, following a three-site clinical trial that met its functional and usability endpoints. Wandercraft set a US commercial launch for 17 September 2026.","formFactor":"exoskeleton","industryVertical":"healthcare","environment":"hybrid","maturityStage":"commercial","lifecycleState":"active","supersededByModelId":null,"specs":{"use":"personal, prescribed take-home use","control":"AI-driven autonomous dynamic balance, hands-free, no crutches; user operates a remote control","regulatory":"FDA cleared August 2026, spinal cord injury at any level for eligible adults","availability":"US commercial launch announced for 17 September 2026","not_disclosed":"price, mass and battery runtime are not stated by Wandercraft","reimbursement":"Medicare DMEPOS pathway for personal exoskeletons exists under billing code K1007"},"manufacturerSerial":null,"reviewStatus":"reviewed","sources":[{"url":"https://www.wandercraft.eu/articles/wandercraft-receives-fda-clearance-for-eve-the-worlds-first-self-balancing-personal-exoskeleton-for-eligible-wheelchair-users-living-with-spinal-cord-injuries-at-any-level","label":"Wandercraft Receives FDA Clearance for Eve","title":"Wandercraft Receives FDA Clearance for Eve","mediaType":"article","sourceName":"Wandercraft"},{"url":"https://www.massdevice.com/wandercraft-wins-fda-clearance-for-self-balancing-exoskeleton/","label":"Wandercraft wins FDA clearance for self-balancing exoskeleton","title":"Wandercraft wins FDA clearance for self-balancing exoskeleton","mediaType":"article","sourceName":"MassDevice"},{"url":"https://exoskeletonreport.com/2026/08/fda-clearance-for-eve-wandercrafts-personal-use-self-balancing-walking-exoskeleton/","label":"FDA Clearance for Eve, Wandercraft's Personal Use Self-Balancing Walking Exoskeleton","title":"FDA Clearance for Eve, Wandercraft's Personal Use Self-Balancing Walking Exoskeleton","mediaType":"article","sourceName":"Exoskeleton Report"},{"url":"https://www.wandercraft.eu/articles/wandercraft-launches-eve-tm-the-worlds-first-self-balancing-personal-exoskeleton-bringing-hands-free-upright-mobility-to-the-home","date":"2026-09-17","title":"Wandercraft Launches Eve US commercial availability","sourceName":"Wandercraft"},{"url":"https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K260381","date":"2026-08-03","title":"FDA 510(k) Premarket Notification K260381 Eve","sourceName":"FDA"},{"url":"https://www.wandercraft.eu/eve","title":"Eve personal exoskeleton","sourceName":"Wandercraft"}],"aliases":["Eve","Wandercraft Personal Exoskeleton"],"collisionRisk":"low","reviewNote":null,"manufacturerTermForTeleop":null,"keyFacts":[{"label":"FDA clearance (regulator, Aug 2026)","value":"510(k) K260381, found substantially equivalent Aug 3 2026, product code PHL (powered exoskeleton)."},{"label":"Cleared use (company-stated)","value":"For eligible adults with spinal cord injury at any level who can operate its remote, on level indoor and adjacent outdoor areas with a trained companion."},{"label":"US launch (company-stated, Sep 2026)","value":"Commercially available from Sep 17 2026; users complete clinical evaluation, custom fitting and companion training before home use."},{"label":"Medicare (company-stated)","value":"Medicare has covered personal exoskeletons since 2024 under code K1007; Wandercraft expected Eve to qualify within 60-90 days of clearance."},{"label":"Battery and motors (company-stated)","value":"4 hours of battery life and 12 motors; hands-free with no crutches."},{"label":"User fit","value":"Users up to 220 lb (100 kg) and 6 ft 4 in (1.94 m), within set ranges for limb length, pelvis width and joint mobility."}],"createdAt":"2026-09-15T04:18:14.198Z","updatedAt":"2026-10-10T03:05:44.511Z","unitsInFieldClaimed":null,"unitsInFieldVerified":null,"unitsManufacturedClaimed":null,"unitsManufacturedVerified":null,"unitsAsOf":null,"unitsSource":null,"salesModel":null,"priceUndisclosedSince":null,"autonomyClass":null,"autonomyStatement":null,"autonomyStatementSource":null,"demoForensics":null,"exportControlClass":null,"minCommitment":null,"warrantyTerms":null,"serviceModel":null,"productionRateClaimed":null,"productionRateEvidenced":null,"teleopRatioDisclosed":null,"interventionRateDisclosed":null,"jsonLd":{"@context":"https://schema.org","@type":"Product","@id":"https://registry.deploy.report/models/wandercraft-eve","url":"https://registry.deploy.report/models/wandercraft-eve","name":"Wandercraft Eve","alternateName":["Eve","Wandercraft Personal Exoskeleton"],"description":"Personal-use self-balancing walking exoskeleton from [Wandercraft](/companies/wandercraft), the take-home counterpart to the clinic-based [Atalante X](/models/wandercraft-atalante-x). Like Atalante it walks hands-free, without crutches, using AI-driven dynamic balance. The FDA cleared Eve in August 2026 for eligible adults with spinal cord injuries at any level, provided the user can operate the device's remote control, following a three-site clinical trial that met its functional and usability endpoints. Wandercraft set a US commercial launch for 17 September 2026.","identifier":"5e7f7d21-4509-40b0-b39d-acd6e2f5ce07","category":"exoskeleton","publisher":{"@id":"https://deploy.report/#organization"}},"framework_metadata":{"framework_schema_version":"0.1.0","verification_status":"verified","maturity_stage":"commercial","lifecycle_state":"active","architectural_position":{"cohort":"exoskeleton","sub_cohorts":[]},"within_cohort_verified_vs_claimed_pair":null,"cap_flags":[],"verification_depth":{"sources_count":6,"primary_source_types":["primary-fda-database"]}}}